The corollary to the right to refuse treatment is the requirement that, in general, informed consent be obtained before treatment. The Declaration of Lisbon recognises this: "The patient has the right to accept or to refuse treatment after receiving adequate information." The information to be given to the patient is of three kinds, but a special problem in relation to the doctrine of informed refusal places a special duty on the doctor to inform the patient about the possible consequences of refusing treatment. Related topics, such as refusal in part, refusal by a parent or guardian, the novus actus interveniens, the living will, and contributory negligence are touched upon.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Acceptability and screening outcomes for hepatitis B, C and human inmunodeficiency virus using rapid diagnostic tests in patients undergoing outpatient endoscopy].
Rev Gastroenterol Peru
January 2025
Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, Chile; Departamento de Gastroenterología, Hospital Sótero del Río, Santiago, Chile.
Introduction: Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections are a global public health concern. In 2019, there were 295.9 million people with chronic hepatitis B and 57.
View Article and Find Full Text PDFEating "rubbish"? Exploring the herbal secrets of "Laji-He," a traditional herbal rice snack from southern China.
J Ethnobiol Ethnomed
January 2025
Lushan Botanical Garden, Jiangxi Province and Chinese Academy of Sciences, Lushan, 332900, China.
Background: Laji-He is a traditional rice-based snack from the Beibu Gulf region in southern China. In the Beibu Gulf region, "Laji-He" (literally "garbage He") signifies the removal of toxins from the body, making it a truly "green" food. Laji-He holds essential cultural and medicinal value, incorporating various medicinal plants into its preparation.
View Article and Find Full Text PDFCommon mental disorders and associated factors among adult patients admitted in non-psychiatric wards of public hospitals in Harari regional State, Eastern Ethiopia.
BMC Psychiatry
January 2025
Department of Psychiatry, Institute of Health, Bule Hora University, Bule Hora, Ethiopia.
Introduction: Common mental disorders represent psychiatric co-morbidity in medical illness, which leads to poor adherence to treatment, increased exposure to diagnostic procedures and the cost of treatment, longer hospital stay, and increasing the risk of complications that result in morbidity and mortality among patients admitted to non-psychiatric wards. There is a dearth of evidence related to the prevalence of common mental disorders and associated factors among adult patients admitted to non-psychiatric wards, particularly in the study area. This study aimed to assess the prevalence of common mental disorders and associated factors among adult patients admitted to non-psychiatric wards of public hospitals in the Harari region, eastern Ethiopia.
View Article and Find Full Text PDFPropensity analysis reveals survival disparities between T1a and T1b well-differentiated thyroid cancer based on surgery.
Gland Surg
December 2024
Division of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, LA, USA.
Background: With rising well-differentiated thyroid cancer (WDTC) incidence, the appropriate treatment choice remains controversial for T1 tumors <2 cm. This study analyzed differences in surgery refusal and survival outcomes between T1a (<1 cm) and T1b (1-2 cm) WDTC, examining the demographic and clinical characteristics associated with patients who decide to either undergo or refuse recommended surgery.
Methods: We studied 81,664 T1N0M0 WDTC patients in the Surveillance, Epidemiology, and End Results (SEER) registry [2000-2019].
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Urol Oncol
January 2025
Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele University, Milan, Italy.
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review we examine the clinical development program of TAR-200, a novel targeted releasing system designed to provide sustained intravesical delivery of gemcitabine to address the needs of patients with NMIBC and of those with MIBC. We describe the concept and design of TAR-200 and the clinical development of this gemcitabine intravesical system in the SunRISe portfolio of studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!